Europe Grants Licensure for Ceprotin (Protein C Concentrate) For Treatment of Protein C Deficiency
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Europe Grants Licensure for Ceprotin (Protein C Concentrate) For Treatment of Protein C Deficiency

BRUSSELS, BELGIUM -- July 19, 2001 -- The European Medicines Evaluation Agency has granted licensure for Ceprotin, protein C concentrate, as a replacement therapy for people with life-threatening blood clotting complications related to severe congenital protein C deficiency.

Baxter is the first company to receive a license using the European centralized procedure, a process by which the European Commission grants authorization that is valid in all member states of the European Union.

Protein C is a component in human plasma that regulates the coagulation system and prevents abnormal clot formation (thrombosis). Currently, there is no ideal alternative to specific protein C replacement therapy. Protein C may be replaced with fresh frozen plasma, but this involves infusing patients with very large volumes of plasma, which can result in fluid overload, causing pulmonary edema and hypertension. Other treatment approaches, such as oral anticoagulation, are associated with a risk of bleeding as well as inadequate control of the serious and widespread thrombotic disorder.

The incidence of severe hereditary protein C deficiency is approximately one in every 200,000 births, and often goes undiagnosed. If left untreated, the thrombotic lesions that develop can result in blindness, severe brain damage, multi-organ failure, and death. Baxter intends to initiate clinical trials in acquired protein C deficiency in the near future.

SOURCE: Baxter International, Inc.

Related Link: Baxter International, Inc.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities